Aldeyra Therapeutics(US:ALDX) TMX Newsfile·2026-04-12 19:01Core Viewpoint - Rosen Law Firm is reminding investors who purchased Aldeyra Therapeutics, Inc. securities between November 3, 2023, and March 16, 2026, of the May 29, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Aldeyra securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by visiting the provided link or contacting the firm directly [3][6]. - The deadline to move the Court to serve as lead plaintiff is May 29, 2026, and a lead plaintiff acts on behalf of other class members [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made false and misleading statements regarding the clinical trials of reproxalap, an Aldeyra drug candidate, leading to unreliable positive findings [5]. - It is claimed that the inconsistency of trial results rendered the defendants' statements about Aldeyra's business and prospects materially false and misleading [5]. - The lawsuit asserts that when the true details were revealed, investors suffered damages as a result [5].